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ABSTRACT
Mechanisms of the Anti-Pneumococcal Function of C-Reactive Protein
by
Toh Boniface Gang
Human C-reactive protein (CRP) increases survival of and decreases bacteremia in mice infected
with Streptococcus pneumoniae. Such protection of mice against pneumococcal infection is seen
only when CRP is administered into mice 6 hours before to 2 hours after the injection of
pneumococci, but not when CRP is given to mice at a later time. Our first aim was to define the
mechanism of CRP-mediated initial protection of mice against infection. It was proposed that
CRP binds to phosphocholine (PCh) moieties present in the cell wall and activates the
complement system on the pneumococcal surface that kills the pathogen. We generated a CRP
mutant F66A/T76Y/E81A incapable of binding to PCh. Mutant CRP did not protect mice from
pneumococcal infection. Thus, the proposed hypothesis was correct; the PCh-binding property of
CRP contributes to the protection of mice against pneumococcal infection. Our second aim was
to investigate why CRP was not protective during the late stages of infection. Pneumococci are
known to recruit an inhibitor of complement activation, factor H, from the host to their surface to
escape complement attack. We considered the ability of CRP, in its nonative form, to bind to
factor H, and generated a CRP mutant E42Q/F66A/T76Y/E81A capable of binding to factor H.
In vivo experiments using the quadruple CRP mutant are in progress. We anticipate that the
combination of wild-type and quadruple mutant CRP should be protective during the late stages
of infection; wild-type CRP would bind to PCh and activate complement while mutant CRP
would cover factor H to prevent its complement-inhibitory activity. Our long-term goal is to
explore the possibility of developing a CRP-based strategy to treat pneumococcal infection.
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ABBREVIATIONS
BSA

Bovine serum albumin

CFU

Colony forming units

CHO

Chinese hamster ovary

CRP

C-reactive protein

ELISA

Enzyme-linked immunosorbent assay

EU

Endotoxin units

h

Hour

HRP

Horseradish peroxidase

i.v.

Intravenous

mAb

Monoclonal antibody

Min

Minute

OD

Optical density

PCh

Phosphocholine

PEt

Phosphoethanolamine

PnC

Pneumococcal C-polysaccharide

SAP

Serum amyloid P component

SDS-PAGE

Sodium dodecyl sulphate polyacrylamide gel electrophoresis

TBS

Tris buffered saline

WT

Wild-type
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CHAPTER 1
INTRODCUTION
C-reactive protein (CRP), a liver-expressed member of the pentraxin family, reacts with
cell wall C-polysaccharide (PnC) of Streptococcus pneumoniae in a Ca2+-dependent manner (13). During bacterial infection, inflammation and injury, its serum levels increase dramatically
(4). This acute surge in plasma levels is seen across the entire evolutionary spectrum, suggesting
that CRP has been evolutionarily conserved. A notable exception to this observation is the
mouse, in which CRP does not show an acute phase response to inflammatory stimuli (5). This
characteristic justifies the suitability of mice for in vivo studies involving the functional
characterization of CRP. CRP has binding specificity for the phosphocholine (PCh) residues
present in PnC (6, 7). CRP also binds to whole pneumococci in human and mouse sera and in
Ca2+-containing buffers (8-11). Serum amyloid P component (SAP), another member of the
pentraxin family, is structurally similar to CRP, and displays Ca2+-dependent binding specificity
for phosphoethannolamine (PEt) (11-13). Although CRP also binds to PEt, such binding is not as
avid as it binds to PCh (11-16). The innate immune properties of CRP seem to be conserved
throughout evolution

Structure of CRP
CRP is composed of 5 identical non-covalently attached subunits or monomers. Based
on the crystallographic data, each subunit has 206 amino acids and the molecular weight
(molecular weight) of each subunit is approximately 23 kDa. All 5 subunits have the same
orientation in the pentamer, with a PCh-binding site located on the same face of each subunit
(17, 18). The PCh-binding site consists of a hydrophobic pocket formed by several amino acids
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including Phe66, Thr76, and Glu81 and 2 Ca2+ ions that are bound to CRP by interactions with
amino acids from other parts of the protein (16, 17, 19-20). The phosphate group of PCh directly
coordinates with the 2 Ca2+ ions. The choline group of PCh lies within the hydrophobic pocket.
Phe66 provides hydrophobic interactions with the 3-methyl groups of choline. Thr76 is critical for
creating the appropriately sized pocket to accommodate PCh. Glu81 interacts with the positively
charged nitrogen atom of choline. Previous mutational analyses of Thr76 in CRP have confirmed
the significance of the hydrophobic pocket for PCh-binding (21). In SAP, at the position
corresponding to Thr76 in CRP, it is a Tyr residue (Tyr74) (22, 23) (Fig. 1.1).

Figure 1.1. The binding of PCh to CRP. The adapted figure shows the positions of the 2 Ca2+
(orange) and a molecule of PCh (Adapted from (16)).
The face opposite to the PCh-binding face of the CRP pentamer, also called the effector
face, consists of a cleft that extends from the center of each monomer to the center of the
pentamer. Key amino acid residues in this cleft are Asp112 and Tyr175, which are responsible for
the binding of C1q, the first step in CRP-mediated complement activation (24, 25). After solving
13

of the C1q structure, it became clear that the positively charged C1q head interacts with the
negatively charged central pore of the CRP protomer (26).

Pneumococcus
S. pneumoniae, commonly called pneumococcus, is the commonest cause of bacterial
community-acquired pneumonia, meningitis, otitis media, and bronchitis (27-29). It commonly
colonizes the upper respiratory tract of man and shows no symptoms of disease. From here it
adapts, proliferates and breaches host barriers to reach the circulatory system, lungs, spleen, and
brain where it causes disease. Children under the age of 5 years, the elderly, and
imunnocompromized individuals constitute the most vulnerable groups.
This vulnerability is related to the emergence of pneumococcal strains that are resistant to
common antibiotics and circumvents host immunity (30). Pneumococcus is a Gram-positive
bacterium surrounded by a cell wall that consists of teichoic acid-containing C-polysaccharide.
Attached to these molecules are PCh residues, which serve as the classical CRP-binding ligand.
Also present within the cell wall are cell wall-anchored pneumococcal surface proteins, cholinebinding proteins, and factor H inhibitor of complement, Hic (Fig. 1.2, next page) (31). Factor H
binds to pneumococci through Hic.
Pneumococcal polysaccharide vaccines have been developed against pneumococcus.
However, these have not been very successful due to the poor immunogenicity of the capsular
polysaccharides and lack of memory immune response in young children (32, 33). Capsular
polysaccharide-related strain variability also contributes to the lack of efficacy in these vaccines.
Conjugate vaccines that couple protein to capsular polysaccharides have been generated without
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success due to high cost that would hinder implementation. Protein-based vaccines are being
explored using candidate pneumococcal surface proteins (34, 35).

Figure 1.2. Structural relationships of surface structures and representation of selected
immunogenic proteins of S. pneumonia. The figures was adapted to illustrate the binding of
CRP to phosphocholine(Adapted from (66))

Functions of CRP
In broad terms, CRP has 2 functions: a recognition function and an effector function. The
recognition function involves the ability of CRP to recognize PCh-containing substances such as
PnC. The effector function involves the ability of PCh-complexed CRP to activate the
complement system. Previous data suggest that protection of mice results from the ability of
CRP to bind to pneumococci and activate complement (36). In mice, however, CRP is only a
trace serum component, not an acute phase protein (5). Mice have been used to explore the in
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vivo functions of human CRP. Passively administered human CRP is protective against lethal
pneumococcal infection, as determined by increased survival of and decreased bacteraemia in
infected mice (10, 36-37). Interestingly, CRP was most effective in protecting mice from
infection only when injected within the range of 6 h before to 2 h after administering
pneumococci into mice (38). The protective function of CRP was not observed when mice
received CRP 24 h or 36 h post infection (10, 38). Thus, the CRP-mediated protection of mice
requires the presence of CRP in the early stages of infection. Mice transgenic for human CRP
were also protected from lethal pneumococcal infection and showed both decreased bacteremia
and increased survival (39). However, the mechanism of CRP in pneumococcal infection has not
been elucidated (5, 40).
CRP also plays a role in inflammatory diseases including atherosclerosis. It has been
shown that CRP prevents the uptake of low density lipoprotein by macrophages, although CRP
was not found to be atheroprotective in vivo (41-42). The plasma level of CRP, however, serves
as an indicator of infection or inflammation states in clinical practice (43).

Factor H and CRP
Factor H is a single chain plasma glycoprotein with molecular weight of 150 kDa. It is
not only constitutively expressed in the liver but is also produced by monocytes, fibroblasts,
endothelial cells, keratinocytes, and platelets (44-46). The plasma circulating concentration of
factor H in humans is between 200-300 g/ml (47-78). It is composed of 20 domains called short
consensus repeats (SCR 1-20), each of which is made up of about 60 amino acids stabilized by 2
internal disulphide bonds. Factor H is the main regulator of the alternative complement pathway
and helps to maintain an anti-inflammatory milieu (49-50). It does this by inhibiting the
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assembly of C3 and C5 convertase enzymes through competition with factor B for C3b binding.
It also facilitates the breakdown of the convertase by displacing bound factor Bb and acting as a
cofactor for factor I in the cleavage and inactivation of C3b (51-52). It is the property of factor H
to polyanionic surface molecules such as glycosaminoglycans and sialic acid that allows it to
regulate complement activation on self surfaces (53).
Recent data suggest that CRP undergoes subtle structural modification under conditions
of acidic pH, high salt concentration, and oxidation (54, 55), and that structurally altered CRP
binds to FACTOR H. There is no evidence of an interaction between CRP and factor H under
conditions of infection and/or inflammation in vivo (56). It was demonstrated that some proteins
can acquire new functions when exposed to different environmental conditions, including post
translational modifications and denaturation. Like immunoglobulins, CRP appears to acquire
new functions based on structural modifications (57, 58). An important gain of function property
is the ability of acidic pH-modified CRP to bind to factor H (54).

Site-Directed Mutagenesis of CRP
Exposure to low pH and oxidation were used to modify CRP and convey new
characteristics/functions. The limitation of these strategies is that they are difficult to replicate in
vivo in order to investigate the functional role of CRP in a homeostatic environment. Thus, our
strategy was to use site-directed mutagenesis to modify CRP to generate CRP with functions not
exhibited by the native protein (Fig. 1.3, next page). The advantage of this approach is that the
CRP mutant generated can be used for in vivo studies.
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Unlike other methods, which may result in transitional state structural change, CRP
modified by mutagenesis undergoes a permanent change that can be verified by sequencing and
assessing properties that were targeted for elimination or introduction.

Figure 1.3. Site-directed mutagenesis of CRP. Based on the crystallographic structure of CRP,
F66A/E81A/T76Y (triple) mutant CRP cDNA was generated using F66A/E81A cDNA as
template. F66A/E81A/T76Y cDNA was in turn used for the generation of
E42Q/F66A/E81A/T76Y (quadruple) mutant CRP cDNA in conjunction with that of E42Q.
The figure was generated using PyMOL (65).

Rationale and Hypotheses
Because PnC-complexed CRP activates the classical complement pathway in both human
and mouse sera (40), it was proposed that CRP is protective through a mechanism in which CRP
binds to pneumococci through PCh groups present on their surface. The pathogen-bound CRP
activates the complement system, and bacteremia is then reduced through complementdependent opsonophagocytosis (59-61). It has also been shown that CRP enhances uptake and
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presentation of pneumococcal antigens through FcγRs on dendritic cells and stimulates
protective adaptive immunity (62). So we hypothesized that if the binding of CRP to PCh is
required for the protection of mice against pneumococcal infection, then a CRP mutant that does
not bind to PCh would not be protective against pneumococcal infection.
Pneumococci have been demonstrated to recruit factor H onto their surface. We
postulated that the bacteria recruit factor H in vivo and exploit its complement regulatory
property to prevent killing through complement activation. In the meantime, it has been
determined that the administration of native CRP into mice later during infection does not
provide protection. Factor H binds to modified forms of CRP (47, 54, 55, 63, and 64). E42Q
CRP mutant that acquired factor H binding ability has been described (54). We suggest that a
CRP mutant that does not bind to PCh but binds to factor H would permit the investigation of the
involvement of factor H in bacterial serum resistance. We used site-directed mutagenesis to
generate a CRP mutant that combines the property of not binding to PCh and binding to factor H
and used it to demonstrate the role of factor H in bacterial infection. Based on this hypothesis,
we proposed that the CRP mutant will bind to factor H on the bacterial surface and prohibit its
complement regulating activity. This would allow WT CRP bound to the bacteria to facilitate
complement activation and deposition.
This project is unique because it provides the opportunity to understand how CRP
accomplishes its protective function against bacterial infection. Data from this study will provide
an insight into how this evolutionarily conserved plasma protein has retained innate properties.
Data generated would contribute to further understanding of how innate immunity evolved and
may provide leads on targeting of community-acquired pneumonia and other pneumococcusassociated diseases.
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Specific Aims

1. To determine whether the binding of CRP to PCh on pneumococci is required for the
protection of mice against initial stages of pneumococcal infection
a. To generate a CRP mutant that does not bind to PCh
b. To determine the protective ability of the CRP mutant generated in aim 1a in a mouse
model of pneumococcal infection


We published the findings and reproduced in chapter 2.

2. To investigate the effects of a CRP mutant capable of binding to factor H on the
protection of mice against late stages of pneumococcal infection
a. To confirm bacterial recruitment of factor H
b. To generate a CRP mutant that binds to factor H
c. To assess binding of the CRP mutant to factor H-coated bacteria
d. To use the CRP mutant in mouse protection experiments


The findings are reported in Chapter 3.
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CHAPTER 2

The Phosphocholine-Binding Pocket on C-reactive Protein is Necessary for Initial Protection of
Mice against Pneumococcal Infection

Toh B. Gang,* David J. Hammond, Jr.,*,1 Sanjay K. Singh,*,1 Donald A. Ferguson, Jr.,*
Vinod K. Mishra,† and Alok Agrawal*

*

Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State

University, TN 37614; and †Department of Medicine, University of Alabama at Birmingham,
Birmingham, AL 35294

Running Title: CRP, PCh , Pneumococcal infection

Corresponding author: Alok Agrawal, Department of Biomedical Science, Quillen College of
Medicine, East Tennessee State University, Johnson City, TN 37614
Phone: 423-439-6336, Fax: 423-439-8044, E-mail: agrawal@etsu.edu

(Reference: Toh B. Gang, David J. Hammond, Jr., Sanjay K. Singh, Donald A. Ferguson,
Jr., Vinod K. Mishra, and Alok Agrawal. J. Biol. Chem. 287: 43116-43125, 2012).
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Abstract
Human CRP protects mice from lethal S. pneumoniae infection when injected into mice 6
h before to 2 h after the administration of pneumococci. Given that CRP binds to PCh containing substances and subsequently activates the complement system, it has been proposed
that the anti-pneumococcal function of CRP requires the binding of CRP to PCh moieties present
in PnC. To test this proposal experimentally, in this study, we utilized a new mutant CRP
incapable of binding to PCh. Based on the structure of CRP-PCh complexes which showed that
Phe66, Thr76 and Glu81 formed the PCh -binding pocket, we constructed a mutant CRP F66AT76Y-E81A in which the pocket was blocked by substituting Thr76 with Tyr. Compared to wildtype CRP, the mutant CRP bound more avidly to PEt and could be purified by affinity
chromatography using PEt-conjugated sepharose. The mutant CRP did not bind to PCh , PnC or
pneumococci. The mutant CRP was free in the mouse serum and its rate of clearance in vivo was
not faster than that of wild-type CRP. When either 25 µg or 150 µg of CRP was administered
into mice, then unlike wild-type CRP, the mutant CRP did not protect mice from lethal
pneumococcal infection. Mice injected with mutant CRP had higher mortality rates than mice
that received wild-type CRP. Decreased survival was due to the increased bacteremia in mice
treated with the mutant CRP. We conclude that the PCh -binding pocket on CRP is necessary for
CRP-mediated initial protection of mice against pneumococcal infection.
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Introduction
CRP, a member of the pentraxin family of proteins, reacts with PnC of S. pneumoniae in a
Ca2+-dependent manner (1-3). The binding specificity of CRP is for the PCh moieties present in
PnC (4). CRP also binds to whole pneumococci in human and mouse sera and in Ca2+-containing
buffers (5-7). Another member of the pentraxin family, serum amyloid P (SAP), which is
structurally similar to CRP, displays Ca2+-dependent binding specificity for PEt (8-10). CRP also
binds to PEt but not as avidly as it does to PCh (4, 8-13).
CRP is composed of 5 identical noncovalently attached subunits. Each subunit has 206
amino acids and the molecular weight of each subunit is approximately 23 kDa (14). All 5
subunits have the same orientation in the pentamer, with a PCh-binding site located on the same
face of each subunit (14, 15). The PCh-binding site consists of a hydrophobic pocket formed by
several amino acids including Phe66, Thr76 and Glu81, and 2 Ca2+ ions, which are bound to CRP
by interactions with amino acids from other parts of the protein (14, 16). The phosphate group of
PCh directly coordinates with the 2 Ca2+ ions. The choline group of PCh lies within the
hydrophobic pocket. Phe66 provides hydrophobic interactions with the 3 methyl groups of
choline. Thr76 is critical for creating the appropriately sized pocket to accommodate PCh. Glu81
interacts with the positively charged nitrogen atom of choline (Fig. 2.1A). Previous mutational
analysis of Thr76 in CRP has confirmed the significance of the hydrophobic pocket for PChbinding (17). In SAP, at the position corresponding to Thr76 in CRP, it is a Tyr (Tyr74) (18, 19).
Pneumococci remain the most common cause of community-acquired pneumonia worldwide (20-22). In humans, CRP is an acute phase protein, that is, its serum concentration is
increased several hundred-fold in response to pneumococcal infection (2). However, the
functions of CRP in pneumococcal infection are not known (3). In mice, CRP is only a trace
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serum component and is not an acute phase protein (23). Therefore mice are used to explore the
in vivo functions of human CRP. In mouse models of infection, passively administered human
CRP has been shown to be protective against lethal pneumococcal infection, as determined by
increased survival of and decreased bacteremia in the infected mice (24, 25). Interestingly, CRP
was most effective in protecting mice from infection only when injected within the range of 6 h
before to 2 h after administering pneumococci into mice (26). The protective function of CRP
was not observed when mice received CRP 24 h or 36 h post infection (7, 26). Thus, the CRPmediated protection of mice requires the presence of CRP in the early stages of infection. Mice
transgenic for human CRP were also protected from lethal pneumococcal infection and showed
both decreased bacteremia and increased survival (27).
Because PnC-complexed CRP activates the complement system, in both human and mouse
sera (3, 28), it has been proposed that CRP is protective through a pathway in which CRP binds
to pneumococci through PCh groups present on their surfaces, the pathogen-bound CRP
activates the complement system, and bacteremia is then reduced through complementdependent opsonophagocytosis (29-31). The aim of this study was to determine whether the
binding of CRP to PCh on pneumococci was required for the protection of mice against
pneumococcal infection. Employing site-directed mutagenesis, we generated a new mutant CRP,
F66A-T76Y-E81A, incapable of binding to PCh, and used the mutant CRP in mouse protection
experiments (Fig. 2.1B). We hypothesized that if the binding of CRP to PCh was required for the
protection of mice against pneumococcal infection, then the mutant CRP should not be
protective.
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Figure 2.1. A subunit of CRP. A, structure of 1 of the 5 subunits of WT CRP bound to PCh (Protein
66
76
81
Data Bank (PDB) ID 1B09) is shown. The side chains of Phe , Thr and Glu involved in the
formation of the PCh-binding pocket are highlighted. Calcium ions (Ca2+) are shown as cyan balls.
B, molecular modeling of triple mutant CRP. The PDB coordinates of mutant CRP were generated
66
76
81
from the PDB file 1B09) using SYBYL (Tripos, Inc.). The side chains of Phe , Thr and Glu are
substituted with Ala, Tyr, and Ala, respectively. 1 of the 5 subunits is shown. The figures were
rendered using PyMOL (66).

Materials and Methods
Construction and expression of the CRP triple mutant F66A/T76Y/E81A
The construction of the F66A-E81A mutant CRP cDNA has been described earlier (13).
The F66A-E81A mutant CRP cDNA was used as the template for construction of the triple
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mutant CRP cDNA (substitution of Phe66 and Glu81 with Ala and of Thr76 with Tyr). Mutagenic
oligonucleotides, 5’-GGATACAGTTTTTACGTGGGTGGGTCTG-3’ and 5’CAGACCCACCCACGTAAAAACTGTATCC-3’, to substitute Thr76 with Tyr (codons shown in
bold and italicised letters), were designed according to the sequence of F66A-E81A mutant CRP
cDNA template and obtained from Integrated DNA Technologies. Mutagenesis was conducted
using the QuikChange site-directed mutagenesis kit (Stratagene). Mutations were verified by
nucleotide sequencing, utilizing the services of the Molecular Biology Core Facility of our
university. Stable transfection of triple mutant CRP cDNA was carried out in CHO cells, as
described previously (7). A CHO cell line expressing the Triple mutant CRP was isolated by a
series of sub-cloning steps.

Preparation of PEt-conjugated sepharose
PEt-conjugated Sepharose was prepared as described previously (32). In brief, 25 ml of
packed ECH-Sepharose 4B beads (GE Healthcare) was first washed with water (pH 4.5) and
subsequently with 0.5 M NaCl. Then, 180 mg of PEt (Sigma-Aldrich, P0503) was dissolved in
25 ml water (pH 4.5) and added to the washed beads. 500 mg of N-(3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (Sigma-Aldrich, E6383) was added to the mixture of PEt and
sepharose beads, and stirred for 1 h at room temperature. After monitoring the pH for 1 h to
ensure that the pH stayed at 4.5, the mixture was left overnight at 4 ºC with slow stirring. The
beads were then washed with 0.1 M acetate buffer, pH 4.0, followed by washing with 100 mM
Tris/HCl, pH 8.0, containing 0.5 M NaCl. Washing was repeated 3 times alternating between the
acetate and Tris buffers. Finally, the beads were washed with water and then with TBS
containing 2 mM CaCl2.
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Purification of native WT CRP
WT CRP was purified from discarded human pleural fluid by affinity chromatography on
a PCh-sepharose column (Pierce) followed by ion-exchange chromatography on a MonoQ
column (GE Healthcare) and gel filtration chromatography on a Superose12 column (GE
Healthcare), as described previously (33), and stored frozen. On the day of the experiments, CRP
was re-purified by gel filtration chromatography on a Superose12 column to remove any form of
modified CRP which might have been generated due to storage of CRP. Re-purified CRP was
stored in TBS containing 2 mM CaCl2 at 4 ºC and was used within a week. The purity of CRP
was confirmed by using denaturing SDS-PAGE.

Purification of triple mutant CRP
Purification of mutant CRP from the cell culture supernatants involved 2 steps: Ca2+dependent affinity chromatography on a PEt-conjugated sepharose column followed by gel
filtration chromatography on a Superose12 column. For affinity chromatography, the culture
media containing CRP was diluted (1:1) in 0.1 M borate buffer saline, pH 8.3, containing 3 mM
CaCl2 and passed through the PEt-conjugated sepharose column. After collecting the flowthrough and washing the column with the same buffer, bound CRP was eluted with 0.1 M borate
buffer saline, pH 8.3, containing 5 mM EDTA. Eluted CRP was concentrated and further
purified by gel filtration chromatography on a Superose12 column. Gel filtration
chromatography was carried out as described for WT CRP, except that the column was
equilibrated and eluted with TBS containing 5 mM EDTA. It was necessary that the gel filtration
chromatography of the mutant CRP be performed in the presence of EDTA because, in the
presence of Ca2+, the mutant CRP bound to Superose beads (data not shown). Eluted CRP was

27

immediately dialyzed against TBS containing 2 mM CaCl2, stored at 4 ºC, and was used within a
week. The purity of CRP was confirmed by using denaturing SDS-PAGE.
The concentration of purified WT and mutant CRP was determined by measuring the OD at
280 nm and using the extinction coefficient value of 19.5. For mouse protection experiments,
both purified WT and mutant CRP were treated with the Detoxi-Gel Endotoxin Removing Gel
according to manufacturer’s instructions (Thermo). The concentration of endotoxin in CRP was
determined by using the Limulus Amebocyte Lysate kit QCL-1000 according to manufacturer’s
instructions (Lonza).

PCh-binding assay
Binding activity of CRP for PCh was evaluated by using PCh-conjugated BSA and PnC
(Statens Serum Institut) as the ligands, as described previously (7, 33). Microtiter wells (96-well
plates) were

-BSA or PnC in TBS, overnight at 4 ºC. The unreacted

sites in the wells were blocked with TBS containing 0.5% gelatin for 45 min at room
temperature. CRP diluted in TBS containing 5 mM CaCl2, 0.1% gelatin and 0.02% Tween-20
(TBS-Ca buffer) was added in duplicate wells. After incubating the plates for 2 h at 37 ºC, the
wells were washed with TBS-Ca buffer. The assays were performed in duplicate plates. In 1
plate, anti-CRP mAb HD2.4, diluted in TBS-Ca buffer, was used (1 h at 37 ºC) to detect bound
CRP. In the other plate, rabbit polyclonal anti-CRP Ab (Sigma-Aldrich), diluted in TBS-Ca
buffer, was used (1 h at 37 ºC) to detect bound CRP. HRP-conjugated goat anti-mouse IgG and
HRP-conjugated donkey anti-rabbit IgG (Thermo), diluted in TBS-Ca buffer, were used (1 h at
37 ºC) as secondary Ab. Color was developed and the OD405 read in a microtiter plate reader
(Molecular Devices).
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Anti-CRP mAb-binding assay
The anti-CRP mAb HD2.4- and EA4.1-binding assays were performed as described
previously (13). Microtiter wells (96-well plates) were coate

anti-CRP mAb

HD2.4 (34, 35) or EA4.1 (34) in TBS, overnight at 4 ºC. The unreacted sites in the wells were
blocked with TBS containing 0.5% gelatin for 45 min at room temperature. CRP diluted in TBSCa buffer was added in duplicate wells. After incubating the plates for 2 h at 37 ºC, the wells
were washed with TBS-Ca buffer. Rabbit polyclonal anti-CRP Ab (Sigma-Aldrich), diluted in
TBS-Ca buffer, was used (1 h at 37 ºC) to detect bound CRP. HRP-conjugated donkey antirabbit IgG (Thermo), diluted in TBS-Ca buffer, were used (1 h at 37 ºC) as secondary Ab. Color
was developed and the OD405 read in a microtiter plate reader (Molecular Devices).

Pneumococci
S. pneumoniae type 3 strain WU2, were made virulent by sequential i.v. passages in
mice, and were stored in aliquots at -80°C in Todd-Hewitt broth containing 0.5% yeast extract
and 10% glycerol, as described previously (7, 28). For each experiment, a separate aliquot of
frozen pneumococci was thawed. Pneumococci were then grown in Todd-Hewitt broth
containing 0.5% yeast extract and collected from mid-log phase cultures. Pneumococci were
washed and resuspended in normal saline (OD600 = 0.35 = 2.5 x 108 CFU/ml). The concentration,
purity and viability of pneumococci were confirmed by plating on blood agar plates.

Pneumococci-binding assay
Microtiter wells (96-well plates) were coated with pneumococci in TBS (107 CFU/100
µl/well) overnight at 4 ºC. The unreacted sites in the wells were blocked with TBS containing
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0.5% gelatin for 45 min at room temperature. CRP diluted in TBS-Ca buffer was added in
duplicate wells. After incubating the plates for 2 h at 37 ºC, the wells were washed with TBS-Ca
buffer. The assays were performed in duplicate plates. The plates were then processed exactly as
described for the PCh-binding assay.
The binding of CRP to pneumococci in the fluid phase was investigated as follows.
Pneumococci (2 x 107 CFU; final concentration 108
M CaCl2 and 0.02% Tween-20, at 37 ºC in
a shaking water bath. After 30 min, pneumococci were pelleted, washed 3 times with the same
buffer, resuspended in TBS, and subjected to denaturing SDS-PAGE.

PEt-binding assay
Binding activity of CRP for PEt was evaluated by using 1-oleoyl-2(1,2-biotinyl
(amidodecanoyl)-sn-glycero-3-PEt (biotinylated-PEt) (Avanti Polar Lipids, 193053) as the
ligand. Stock biotinylated-PEt (1 mg/ml in choloroform) was nitrogen-bubbled for 5 min to
evaporate chloroform and then air-dried for 1 h at room temperature to evaporate residual
chloroform. Biotinylated-PEt was resuspended in 1 ml ethanol, aliquoted, and stored at -20 ºC.
Microtiter wells (96-

-Aldrich,

A9275) in TBS, for 2 h at 37 ºC. The unreacted sites in the wells were blocked with TBS
containing 0.5% gelatin for 45 min at room temperature. After washing the wells with TBS,
biotinylated-PEt
washing the wells with TBS-Ca buffer, CRP diluted in TBS-Ca buffer was added in duplicate
wells. After incubating the plates overnight at 4 ºC, the wells were washed with TBS-Ca buffer.
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The assays were performed in duplicate plates. The plates were then processed exactly as
described for the PCh-binding assay.
Streptavidin could not be used to capture biotinylated PEt on the wells because, in
preliminary experiments, CRP was found to bind to streptavidin (data not shown). This was not
the case with avidin coating (data not shown).

Mice
Male C57BL/6J mice (Jackson ImmunoResearch Laboratories) were brought up and
maintained according to protocols approved by the University Committee on Animal Care. Mice
were 8-10 week old when used in experiments.

Mouse protection experiments
Two separate mouse protection experiments were performed using 2 batches of purified
WT and mutant CRP. Mice were first injected i.v. with either 25 µg or 150 µg of WT or triple
mutant CRP in 150 µl TBS containing 2 mM CaCl2. The endotoxin content in 25 µg and 150 µg
WT CRP was 0.18±0.09 EU and 1.08±0.52 EU, respectively. The endotoxin content in 25 µg
and 150 µg mutant CRP was 0.16±0.09 EU and 0.93±0.54 EU, respectively. After 30 min, mice
were injected i.v. with 5 x 107 CFU (based on OD600) of pneumococci in 100 µl of saline. The
actual number of pneumococci injected, based on the plating results obtained next day, was
5.15±0.13 x 107 CFU. Survival of mice was recorded 3 times per day for 7 d. Survival curves
were generated using the GraphPad Prism 4 software. To determine p values for the differences
in the survival curves among various groups, the survival curves were compared using the
software’s Logrank test. To determine bacteremia (CFU/ml) in the surviving mice, blood was
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collected daily for 5 d from the tip of the tail vein, diluted in normal saline, and plated on blood
agar plates for colony counting. Bacteremia values for dead mice was taken as >108 CFU/ml,
because mice died when the bacteremia exceeded 108 CFU/ml. The plotting and statistical
analyses of the bacteremia data were done using the GraphPad Prism 4 software and MannWhitney two-tailed t-test.

Clearance of CRP from mouse circulation
Mice were injected i.v. with 100 µg of CRP in TBS containing 2 mM CaCl2 through the
tail. Blood was collected from the tip of the tail vein at various times up to 30 h. The
concentration of CRP in the serum was measured by ELISA (13). The statistical analysis of the
data was performed using the Mann-Whitney two-tailed t-test.

Repurification of CRP from purified triple mutant CRP-spiked mouse serum
Purified triple mutant CRP (1 mg) was added to 2 ml C57BL/6 mouse serum (Innovative
Research) and incubated for 30 min at 37 ºC. The final volume was then increased to 10 ml by
adding 0.1 M borate buffer saline, pH 8.3, containing 3 mM CaCl2. The mutant CRP was
repurified by Ca2+-dependent affinity chromatography on the PEt-conjugated sepharose column,
as described above. After collecting the flow-through and washing the column with the same
buffer, bound CRP was eluted with 0.1 M borate buffer saline, pH 8.3, containing 5 mM EDTA.
To control the experiment, mouse serum alone (2 ml), without spiking with purified mutant CRP,
was used. The EDTA eluates were subjected to denaturing SDS-PAGE.
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Results
Characterization of the CRP triple mutant
The mutant CRP cDNA was successfully expressed in CHO cells and could be purified
by PEt-affinity chromatography followed by gel filtration chromatography. The elution profiles
of WT CRP and mutant CRP from the gel filtration column were almost overlapping; the elution
volume of the mutant CRP was only 250 µl less than that of WT CRP (Fig. 2.2A). Denaturing
SDS-PAGE analysis of purified WT CRP and mutant CRP showed single bands and the
molecular weight of the subunits of mutant CRP was same as that of WT CRP (Fig. 2.2B). We
also evaluated the epitope for the anti-CRP mAb HD2.4. The mAb HD2.4 is a pentameric CRPspecific Ab and its epitope is located on the face opposite to the PCh-binding face of the CRP
pentamer (34, 36). As shown in Fig. 2.2C, both WT and mutant CRP recognized the mAb HD2.4
equally well. These data demonstrated that the substitution of Phe66, Thr76 and Glu81 with Ala,
Tyr and Ala, respectively, did not affect the overall structure of CRP and that the mutant CRP
was pentameric.

The CRP triple mutant binds neither PCh nor pneumococci
The PCh-binding activity of the mutant CRP was assessed by using 2 different PChcontaining ligands, PCh-BSA and PnC. WT CRP bound to both ligands in a CRP concentrationdependent manner, but the mutant CRP neither bound to PCh-BSA (Fig. 2.3A) nor to PnC (Fig.
2.3B). We characterized the PCh-binding site using the anti-CRP mAb EA4.1 also. The binding
of this mAb to CRP is Ca2+-dependent, and can be inhibited by PCh, indicating that EA4.1 binds
at or near the PCh-binding site (34). As shown in Fig. 2.3C, the mutations decreased the binding
of CRP to EA4.1 by approximately 99%; for equivalent binding to EA4.1, 100 ng/ml of mutant
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CRP was required compared to 1 ng/ml of WT CRP, indicating that the EA4.1-binding epitope,
and hence the PCh-binding site, on the mutant CRP was lost.

Figure 2.2. Overall pentameric structure of the CRP triple mutant F66A/T76Y/E81A. A, Elution
profiles of WT and mutant CRP from the superose12 gel filtration column are shown. WT CRP (1.0
mg) in TBS containing 2 mM CaCl2 was applied to the equilibrated column and eluted with the same
buffer. Mutant CRP (0.95 mg) in TBS containing 5 mM EDTA was applied to the equilibrated
column and eluted with the same buffer. Sixty fractions (0.25 ml) were collected and protein
measured (OD280) to determine the elution volume of CRP from the column. A representative of 3
experiments is shown. B, Denaturing SDS-PAGE (4%-20% gel) of CRP (5 mg). A representative gel,
stained with Coomassie brilliant blue, is shown. C, microtiter wells were coated with anti-CRP mAb
HD2.4. The unreacted sites in the wells were blocked with gelatin. Purified CRP diluted in TBS-Ca
buffer was then added to the wells. Bound CRP was detected by using rabbit polyclonal anti-CRP
antibody and HRP-conjugated donkey anti-rabbit IgG. Color was developed, and the absorbance was
read at 405 nm. A representative of 3 experiments is shown.
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Figure 2.3. PCh-binding site of CRP. A and B, microtiter wells were coated with PCh-BSA (A) and
PnC (B). The unreacted sites in the wells were blocked with gelatin. Purified CRP diluted in TBSCa buffer was then added to the wells. Bound CRP was detected by using anti-CRP mAb HD2.4 and
HRP-conjugated goat anti-mouse IgG. Color was developed, and the absorbance was read at 405
nm. A representative of 4 experiments is shown. Similar results were obtained when polyclonal antiCRP antibody was used to detect ligand-bound CRP (data not shown). C, microtiter wells were
coated with anti-CRP mAb EA4.1. The unreacted sites in the wells were blocked with gelatin.
Purified CRP diluted in TBS-Ca buffer was then added to the wells. Bound CRP was detected by
using rabbit polyclonal anti-CRP antibody and HRP-conjugated donkey anti-rabbit IgG. Color was
developed, and the absorbance was read at 405 nm. A representative of 3experiments is shown.

We also determined the binding of mutant CRP to whole pneumococci that were used in
the mouse protection experiments. In the solid phase pneumococci-binding assay, the mutant
CRP did not bind to whole pneumococci (Fig. 2.4A). In the fluid phase binding assay also, the
mutant CRP did not bind to pneumococci (compare lanes 4 and 5 in Fig. 2.4B). Thus, the Triple
mutant CRP binds neither PCh nor pneumococci.
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Figure 2.4. Binding of CRP to pneumococci. A, microtiter wells were coated with pneumococci.
The unreacted sites in the wells were blocked with gelatin. Purified CRP diluted in TBS-Ca buffer
was then added to the wells. Bound CRP was detected by using anti-CRP mAb HD2.4 and HRPconjugated goat anti-mouse IgG. Color was developed, and the absorbance was read at 405 nm. A
representative of 4 experiments is shown. Similar results were obtained when polyclonal antiCRP antibody was used to detect ligand-bound CRP (data not shown). B, a representative
denaturing SDS-PAGE gel (4–20%) stained with Coomassie Brilliant Blue is shown. Lane 1,
purified WT CRP (5 μg); lane 2, purified mutant CRP (5 μg); lane 3, pneumococci alone; lane 4,
pneumococci after mixing with WT CRP; lane 5, pneumococci after mixing with mutant CRP.
Because the substitution of Thr76 to Tyr was based on the structure of SAP, and SAP
binds to PEt (8-10), we next evaluated the effects of the mutations on the binding of CRP to PEt.
Both, WT CRP and mutant CRP bound to PEt in a CRP concentration-dependent manner (Fig.
2.5). However, the mutant CRP was much more efficient than WT CRP in binding to PEt. For
equivalent binding to PEt, 10 g/ml of WT CRP was required compared to 170 ng/ml of mutant
CRP. By repeating the PEt-binding assays 4 times, we found that approximately 98% less of
mutant CRP was required compared to WT CRP for equivalent binding to PEt. Thus, the triple
mutant CRP binds to PEt more avidly than WT CRP does.
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Figure 2.5. Binding of CRP to PEt. Microtiter wells were first coated with avidin in TBS. The
unreacted sites in the wells were blocked with gelatin. Biotinylated PEt diluted in TBS was then
added to the wells. After washing the wells with TBS, purified CRP diluted in TBS-Ca buffer was
added to the wells. Bound CRP was detected by using anti-CRP mAb HD2.4 and HRP-conjugated
goat anti-mouse IgG. Color was developed and the OD was read at 405 nm. A representative of 4
experiments is shown. Similar results were obtained when polyclonal anti-CRP Ab was used to
detect PEt-bound CRP (data not shown).

In the ligand-binding assays (Figs. 2A, 2B, 3A, and 4), similar results were obtained
irrespective of which anti-CRP Ab, the anti-CRP mAb HD2.4 (data shown) or polyclonal antiCRP Ab (data not shown), was used to detect ligand-bound CRP. Because the mAb HD2.4 is a
pentameric CRP-specific Ab (34, 36), the ligand-binding data further suggested that the overall
structure of the mutant CRP was not different from that of WT CRP.
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The CRP triple mutant does not protect mice from pneumococcal infection
Fig. 2.6A shows the combined results of 2 separate protection experiments using 25 µg of
CRP and 6 mice in each group in each experiment. The median survival time (the time taken for
the death of 50% of mice) for mice injected with bacteria alone (control group A) was 40 h. The
median survival time for mice injected with bacteria and WT CRP (group B) was 88 h. The
median survival time for mice injected with bacteria and the mutant CRP (group C) was 44 h. In
WT CRP-treated group, no deaths occurred in 44 h, and 25% mice survived up to 7 d. By the end
of the 3rd day, all mice died in the mutant CRP-treated group while the survival was 58% in WT
CRP-treated group. Fig. 2.6B shows the combined results of 2 separate protection experiments
using 150 µg of CRP and 6 mice in each group in each experiment. The median survival time for
mice injected with bacteria and WT CRP (group D) was 92 h. The median survival time for mice
injected with bacteria and the mutant CRP (group E) was 46 h. In WT CRP-treated group, no
deaths occurred in 46 h, and 17% mice survived up to 7 d. By the end of the 3rd day, 75% mice
survived in WT CRP-treated group compared to only 25% in the mutant CRP-treated group. By
the end of the 4th day, all mice died in the mutant CRP-treated group while the survival was 25%
in WT CRP-treated group. Thus, similar results were obtained when mice were given either 25
µg CRP or 150 µg CRP; in contrast to WT CRP, the mutant CRP did not decrease mortality and
did not prolong survival of infected mice. Because 25 µg of WT CRP was protective and the
mutant CRP was not protective even when used at 150 µg that is, at 6-times more than the
protective dose, we conclude that the CRP-mediated protection of mice from infection is
dependent upon the PCh-binding activity of CRP.
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Figure 2.6. Survival curves of mice infected with S. pneumoniae with 150 g of CRP. Mice
7
were injected with 5 x 10 CFU pneumococci, with or without 150 mg of either WT or mutant
CRP. CRP was injected first; bacteria were injected 30 min later. Deaths were recorded 3 times a
day for 7 days. The data are combined from 3 separate experiments with 6-8 mice in each group
in each experiment. The p values for the differences in the survival curves among groups A/B,
A/C, and B/C are <0.0001, <0.0001 and 0.49, respectively.
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Fig. 2.7 shows the bacteremia values in mice from the protection experiment shown in Fig. 5.
Based on the median bacteremia values, in mice injected with bacteria alone (group A), 1 day
post infection, bacteremia was approximately 5.8 x 104 CFU/ml of blood. In mice injected with
bacteria and 25 µg WT CRP (group B), bacteremia was 8.4 x 102 CFU/ml 1 day post infection.
In mice injected with bacteria and 150 µg WT CRP (group D), bacteremia was 2.5 x 103 CFU/ml
1day post infection. However, in mice injected with bacteria and 25 µg mutant CRP (group C),
1 day post infection, bacteremia was 5.9 x 105 CFU/ml. In mice injected with bacteria and 150
µg mutant CRP (group E), 1day post infection, bacteremia was 2.3 x 105 CFU/ml. In groups A,
C and E, bacteremia increased dramatically after day 1, and mice died once bacteremia exceeded
108 CFU/ml. In mice administered with WT CRP, there was an increase in bacteremia past day
1, but it took another 2 days to exceed 108 CFU/ml when those mice died, compared to <1 day
for the WT CRP-treated group. Statistically significant differences in bacteremia were observed
between the control (group A) and WT CRP-treated groups (groups B and D), and between the
WT CRP-treated and the mutant CRP-treated groups (groups C and E), until day 2. These results
indicated that the increased resistance to infection in WT CRP-treated mice was associated with
slower increase in bacteremia and that the PCh-binding activity of CRP was critical in this
process.

The CRP triple mutant stays free in the mouse serum and its clearance rate in vivo is not faster
than that of WT CRP
Although the mutant CRP did not protect mice from infection even when used at an amount
which was 6-times higher than the protective dose for WT CRP, we determined the rate of
clearance of mutant CRP from mouse circulation and compared it with that of WT CRP to
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confirm that the mutant CRP was not protective because of its inability to bind pneumococci and
not because of its faster clearance in vivo.

Figure 2.7. Bacteremia in mice treated with or without 150 g of either WT or triple mutant CRP.
Blood samples were collected from each surviving mouse shown in Fig. 7 for the first 5 days postinfection. Bacteremia was determined by plating. Each dot represents 1 mouse. The horizontal line
in each group of mice represents the median value of bacteremia in that group. A bacteremia value
8
of >10 indicates a dead mouse. The p values for the differences between groups A/B, A/C, and B/C,
on day 1, are <0.0001, <0.0001 and 0.44, respectively. The p values for the differences between
groups A/B, A/C, and B/C, on day 2, are <0.0001, <0.0001 and 0.19, respectively.

The average slope of the 4 clearance curves for WT CRP was -0.67±0.02 (Fig. 2.8A) and the
average slope of the 4 clearance curves for mutant CRP was -0.33±0.03 (Fig. 2.8B). Although
the rate of clearance of mutant CRP (0.33 g/ml/h) was significantly different (p = 0.03) from
that of WT CRP (0.67 g/ml/h), the clearance of mutant CRP was not faster than that of WT
CRP. These data suggested that the mutations did not confer instability to the mutant CRP in
vivo.
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Figure 2.8. Clearance of CRP from mouse circulation. Mice were injected with 100 mg of CRP in TBS
containing 2 mM CaCl2. Blood was collected at various time points, sera separated, and the
concentration of CRP measured. The time at which the CRP concentration in serum was at its peak
was considered as zero time and the CRP concentration at this time was taken as 100% injected CRP;
clearance of CRP was then followed at various time intervals.

Although the clearance data also suggested that the mutant CRP was free in circulation and
available for functions because it reacted with anti-CRP mAb HD2.4, we used another approach
to confirm that the mutant CRP was free in the mouse serum and was not sequestered by any
other serum protein. As shown in Fig. 2.9, the mutant CRP present in the mouse serum bound to
PEt in a Ca2+-dependent manner and could be eluted with EDTA (lane 3). Besides CRP, no
additional bands were seen when compared with the nonspecific bands seen with the serum alone
control (compare lanes 3 and 4). Successful repurification of the mutant CRP from the mutant
CRP-spiked mouse serum further suggested that the mutant CRP was free in the mouse serum
and was not sequestered by any other serum protein.
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Figure 2.9. Repurification of CRP triple mutant from purified mutant CRP-spiked mouse serum. A
representative denaturing SDS-PAGE gel (4–20%) stained with Coomassie Brilliant Blue is shown.
Lane 1, molecular mass markers; lane 2, purified mutant CRP (5 μg); lane 3, EDTA eluate (25 μl,
A280 1.13) from the PEt affinity chromatography column through which mouse serum containing
mutant CRP was passed in the presence of CaCl2; lane 4, EDTA eluate (25 μl, A280 0.29) from the
PEt affinity chromatography column through which mouse serum alone was passed in the presence
of CaCl2.
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Discussion
In this study, we tested the hypothesis that the CRP-mediated protection of mice from
pneumococcal infection is dependent upon the PCh-binding activity of CRP. We mutated 3
amino acids in the PCh-binding pocket of CRP in order to generate a mutant CRP incapable of
binding to PCh. We then compared the protective ability of WT CRP with that of mutant CRP.
Our major findings were: 1. Substitution of Phe66, Thr76 and Glu81 with Ala, Tyr and Ala,
respectively, abolished the PCh-binding, PnC-binding and pneumococcus-binding activity of
CRP. 2. The triple mutant CRP was more efficient than WT CRP in binding to PEt. 3. Mutations
in the PCh-binding pocket of CRP did not affect the overall pentameric structure of CRP. 4. The
triple mutant CRP stayed free in the mouse serum and its clearance rate in vivo was not faster
than that of WT CRP. 5. At both 25 µg and 150 µg the triple mutant CRP did not protect mice
from pneumococcal infection.
Previously, we tested the same hypothesis that the CRP-mediated protection of mice from
pneumococcal infection is dependent upon the PCh-binding activity of CRP (7). The mutant
CRP used in the earlier investigation was a CRP double mutant, F66A-E81A, which also does
not bind to PCh, PnC or pneumococci (7, 13). We reported that the F66A-E81A mutant CRP was
as capable as WT CRP in protecting mice from pneumococcal infection, which was a surprising
finding (7). This and the following 3 points prompted us to make another mutant CRP incapable
of binding to PCh and repeat the mouse protection experiments. First, we wanted to use a mutant
CRP, incapable of binding to PCh, with more drastic changes in the PCh-binding pocket. We
wanted to block the pocket. In the earlier F66A-E81A double mutant, although 2 residues were
mutated, the pocket was not blocked. Second, we wanted to use freshly purified CRP in all
experiments. Third, because we were now successful in establishing a mouse model of

44

pneumococcal infection in which 25 µg CRP was protective, as has been shown by others (25,
26), we wanted to use 2 different doses of CRP (25 µg and 150 g) in protection experiments.
Previously (7), we only used 1 dose of CRP, 150 g.
As shown in Fig. 9A, Phe66, Thr76 and Glu81 participate in CRP-PCh interaction (16). To
generate a mutant CRP incapable of binding to PCh, our mutagenesis plan included mutating all
3 amino acids. Based on the structure of SAP (18), we mutated Thr to Tyr, and added the T76Y
mutation to our previously published mutant CRP, F66A-E81A. Molecular modelling of the
triple mutant CRP showed that the large side chain of Tyr could partially block the PCh-binding
pocket (Fig. 2.1B). Loss of binding of triple mutant CRP to PCh, but dramatically enhanced
binding to PEt, further indicated that the PCh-binding pocket was blocked in the mutant CRP.
Also, it was easier to purify this mutant CRP by affinity chromatography due to its strong avidity
for PEt. Interestingly, like SAP (9, 10, 37, 38), the mutant CRP exhibited carbohydrate-binding
property; in the presence of Ca2+, the mutant CRP bound to agarose beads used for gel filtration
chromatography (data not shown).
CRP binds to FcγR (39-41), the FcγR have been implicated in the protection against
pneumococcal infection in mice (42), and CRP has been shown to enhance uptake and
presentation of pneumococcal antigens through FcγR on dendritic cells and stimulate protective
adaptive immunity (43). However, we did not characterize the mutant CRP for binding to FcγR
because FcγR do not participate in CRP-mediated protection of mice against pneumococcal
infection; CRP was equally protective in WT and FcγR knockout mice (44). We did not
characterize the mutant CRP for activating the complement system because CRP activates
complement only when ligand-complexed (30), but the mutant CRP was unable to complex with
PCh-BSA, PnC or pneumococci.
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We used a high dose, 5 x 107 CFU, of pneumococci in mouse protection experiments.
This dose of bacteria was necessary, because endogenous mouse CRP might have been
protective against lower doses of bacteria. It has been reported that endogenous mouse CRP is
also protective against pneumococcal infection in mice; the LD50 of pneumococci was drastically
reduced in CRP knockout mice (45). We used 25 µg and 150 µg CRP in mouse protection
experiments, however, we also found that even 10 µg of WT CRP was protective (data not
shown), as has been reported earlier (24-26). Our finding that WT CRP was protective while
mutant CRP was not protective even at 150 µg dose clearly indicated that the PCh-binding
pocket in CRP was critical for the initial protection of mice from pneumococcal infection. Our
findings are consistent with other reports which showed that the PCh on pneumococci mediated
the function of CRP to block the attachment of pneumococci to platelet-activating factor
receptors on human pharyngeal epithelial cells and that the PCh-binding activity of CRP was
required for the protection of mice from challenge with platelet-activating factor (46, 47).
Because CRP protects mice from infection only when injected within the range of 6 h
before to 2 h after administering pneumococci, and not when injected 24 h or 36 h post infection
(7, 26), we conclude that CRP is able to use the PCh-binding-based mechanism for the protection
of mice only during the early stages of infection. It has been shown that native CRP undergoes
structural transformations under several different experimental conditions (3, 33, 48-53). It has
also been shown that structurally altered, or slightly-to-completely denatured, CRP is capable of
binding to immobilized factor H (3, 33, 51-56). Factor H is a regulator of complement activation
and has been implicated in the resistance of pneumococci to complement attack (3, 57-59). It
remains to be investigated whether such CRP-factor H interaction plays any role in the CRPmediated protection of mice from pneumococcal infection. However, the combined data indicate

46

that the CRP-mediated protection of mice requires the presence of CRP during the early stages of
infection.
The outcome of the in vivo experiments obtained with the use of the triple mutant CRP in
this investigation were different from the results obtained with the use of the CRP double mutant
reported earlier (7); the reasons behind this difference are not clear. Both mutants do not bind to
PCh, PnC or pneumococci. The only differences in the ligand-binding properties of the2 mutants
were toward their binding avidity for PEt and mAb EA4.1 (supplemental Fig. 2.1), which do not
explain the differences in the outcome of the in vivo experiments. Whether the difference in the
results of the 2 in vivo experiments was due to the difference in the protective ability of WT CRP
in the 2 animal model systems, or due to the difference in the ages of purified CRP, remains to
be explored. Development of infection models involving passively administered human WT and
mutant CRP in CRP knockout mice (45, 60-62) and SAP knockout mice (63-65), and also the
development of mice transgenic for mutant CRPs may provide more information on the
mechanisms of anti-pneumococcal function of CRP in protecting mice against early and late
stages of infection.
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Abstract
Human CRP protects mice from lethal S. pneumoniae infection when injected into mice 6 h
before to 2 h after the administration of pneumococci. However, when injected at 36 h after
infection, CRP does not offer any protection against pneumococcal infection in mice. Because
pneumococci have been shown to recruit factor H, we proposed that the 36 h serum resistance
observed with pneumococci is due to the complement-inhibitory property of pneumococci-bound
factor H. To investigate the role of factor H in pneumococcal serum resistance, we employed
site-directed mutagenesis of CRP to generate a mutant which binds to factor H but does not bind
to PCh. Based on the factor H-binding property of a previously reported CRP mutant E42Q, we
added the E42Q mutation to CRP triple mutant F66A/T76Y/E81A incapable of binding to PCh.
We constructed and expressed CRP quadruple mutant E42Q/F66A/T76Y/E81A. Unlike wildtype CRP, mutant CRP bound avidly to factor H immobilized on microtiter wells but did not
bind to PCh-BSA, PnC, or pneumococci. Mutant CRP also bound to in vitro-prepared factor Hcoated pneumococci as well as to factor H-coated pneumococci isolated from the infected mice.
The rate of clearance of mutant CRP from mouse circulation was similar to that of wild-type
CRP. These results suggest that quadruple mutant CRP may be able to bind to serum resistant
pneumococci through immobilized factor H and render them susceptible by neutralizing the
complement inhibitory properties of factor H. In vivo experiments using the quadruple CRP
mutant are in progress. We anticipate that the combination of wild-type and quadruple mutant
CRP should be protective during the late stages of infection; wild-type CRP would bind to PCh
and activate complement while mutant CRP would cover factor H to prevent its complementinhibitory activity. Our long-term goal is to explore the possibility of developing a CRP-based
strategy to treat pneumococcal infection.
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Introduction
C-reactive protein is a member of the pentraxin family of proteins which reacts with PnC
of S. pneumoniae in a Ca2+-dependent manner (1, 2, 3). The binding specificity of CRP is for the
PCh residues present in PnC (4). CRP also binds to whole pneumococci in humans (5, 6, 7).
Another member of the pentraxin family, serum amyloid P component (SAP), which is
structurally similar to CRP, displays Ca2+-dependent binding specificity for PEt (8, 9, 10). CRP
also binds to PEt but not as avidly as it binds to PCh (8, 9, 10, 11, 12, and 13).
CRP is composed of 5 identical non-covalently attached subunits. Each subunit has 206
amino acids and the molecular weight of each subunit is approximately 23 kDa (14). All 5
subunits have the same orientation in the pentamer, with a PCh-binding site located on the same
face of each subunit (14, 15). The PCh-binding site consists of a hydrophobic pocket formed by
several amino acids including Phe66, Thr76 and Glu81, and 2 Ca2+ ions which are bound to CRP by
interactions with amino acids from other parts of the protein (14, 16). The phosphate group of
PCh directly coordinates with the 2 Ca2+ ions. The choline group of PCh lies within the
hydrophobic pocket. Phe66 provides hydrophobic interactions with the 3 methyl groups of
choline. Thr76 is critical for creating the appropriately sized pocket to accommodate PCh. Glu81
interacts with the positively charged nitrogen atom of choline. Previous mutational analyses of
Thr76 in CRP have confirmed the significance of the hydrophobic pocket for PCh-binding (17).
In SAP, at the position corresponding to Thr76 in CRP, it is a Tyr residue (Tyr74) (18, 19). The
Tyr may play a role in the high binding avidity of SAP to PEt.
In humans, CRP is an acute phase protein, that is, its serum concentration is increased
several hundred-fold in response to pneumococcal infection (2). The functions of CRP, however,
in pneumococcal infection are not known (20, 21). In mice, however, CRP is only a trace serum
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component, not an acute phase protein (22). Mice have been used to explore the in vivo functions
of human CRP. Passively administered human CRP has been shown to be protective against
lethal pneumococcal infection, as determined by increased survival of and decreased bacteremia
in the infected mice (7, 23, 24). Interestingly, CRP was most effective in protecting mice from
infection only when injected within 6 h before and 2 h after administering pneumococci into
mice (25). The protective function of CRP was not observed when mice received CRP 36 h post
infection (7, 25). Thus, the CRP-mediated protection of mice requires the presence of CRP in the
early stages of infection. The failure of CRP to protect mice during late stage of infection is
inexplicable. Mice transgenic for human CRP were also protected from lethal pneumococcal
infection and showed both decreased bacteremia and survival (26).
Pneumococci, like many bacteria, have been demonstrated to recruit factor H onto their
surface (27, 28, 29, 30). The possible involvement of pneumococci-recruited factor H in bacterial
serum resistance is a question that warrants investigation. Factor H is a single chain plasma
glycoprotein with molecular weight of 150 kDa. It is not only constitutively expressed in the
liver but is also in monocytes, fibroblasts, endothelial cells, keratinocytes, and platelets (31, 32,
33). The plasma circulating concentration of factor H in humans is between 200-300 g/ml (34,
35). It is composed of 20 domains called short consensus repeats (SCR 1-20), each of which is
made up of about 60 amino acids stabilized by 2 internal disulphide bonds. Factor H is the main
regulator of the alternative complement activation pathway and helps to maintain an antiinflammatory milieu (36, 37). It does this by inhibiting the assembly of C3 and C5 convertase
enzymes through competition with factor B for C3b binding. It also facilitates the breakdown of
the convertase by displacing bound factor Bb and acting as a cofactor for factor I in the cleavage
and inactivation of C3b (38, 39).
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There is limited evidence of an interaction between pentameric CRP and factor H under
conditions of infection and/or inflammation (40). However, modified forms of CRP have been
shown to bind readily to factor H (34, 40, 41, 42, 43, 44). The E42Q mutant CRP, with factor H
binding ability has been described (45). PnC-complexed CRP activates the classical complement
pathway in both human and mouse sera (21). We have demonstrated earlier that CRP is
protective through a mechanism in which CRP binds to pneumococci through PCh groups
present on their surface only during the early stages of infection (46). It has also been shown that
CRP enhances uptake and presentation of pneumococcal antigens through FcγRs on dendritic
cells and stimulates protective adaptive immunity (47). The observation that administration of
CRP to mice infected with pneumococci at 36 h does not offer protection suggests that there is
an undefined mechanism that operates during the later stages of pneumococcal infection. We
hypothesized that the bacteria recruit factor H in vivo and exploit its complement regulatory
ability to prevent complement activation by the host. We suggested that a mutant CRP that does
not bind to PCh but binds to factor H would allow us to investigate the involvement of factor H
in bacterial serum resistance. We employed site-directed mutagenesis to generate a mutant CRP
that combines the property of not binding to PCh and binding to factor H and used it to
demonstrate the role of factor H in bacterial infection. Based on the above hypothesis, we
proposed that the mutant CRP would bind to factor H on the bacterial surface and neutralize its
complement regulating activity. This would allow WT CRP bound to the bacteria to facilitate
complement activation and deposition when administered to mice during late stage
pneumococcal infection.

63

Materials and Methods
Construction and expression of the CRP quadruple mutant E42Q/F66A/T76Y/E81A
The construction of the triple mutant CRP cDNA has been described earlier (46). The
triple mutant CRP cDNA was used as the template for construction of the quadruple mutant
quadruple mutant CRP cDNA (substitution of Glu42 with Gln, Phe66 & Glu81 with Ala and of
Thr76 with Tyr). Mutagenic oligonucleotides, 5’-C CAC TTC TAC ACG CAA CTG TCC TCG
ACC-3’ and 5’-GGT CGA GGA CAG TTG CGT GTA GAA GTG G-3’, to substitute Glu42 with
Gln (codons shown in bold and italicized letters), were designed according to the sequence of
triple mutant CRP cDNA template and obtained from Integrated DNA Technologies.
Mutagenesis was conducted using the Quick Change site-directed mutagenesis kit (Stratagene).
Mutations were verified by nucleotide sequencing, utilizing the services of the Molecular
Biology Core Facility of the university. Stable transfection of the quadruple mutant CRP cDNA
was carried out in CHO cells, as described previously (7). A CHO cell line expressing the
Quadruple mutant CRP was isolated by a series of sub-cloning steps.

Purification of WT CRP
WT CRP was purified from discarded human pleural fluid by affinity chromatography on
a PCh-sepharose column (Pierce) followed by ion-exchange chromatography on a MonoQ
column (GE Healthcare) and gel filtration chromatography on a Superose12 column (GE
Healthcare), as described previously (44), and stored frozen. On the day of the experiments, CRP
was re-purified by gel filtration on a Superose12 column to remove any form of modified CRP
which might have generated due to storage of CRP. Re-purified CRP was stored in TBS
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containing 2 mM CaCl2 at 4 ºC and was used within a week. The purity of CRP was confirmed
by using denaturing SDS-PAGE.

Purification of CRP quadruple mutant
Purification of mutant CRP from the cell culture supernatants involved 2 steps: Ca2+dependent affinity chromatography on a PEt-conjugated sepharose column followed by gel
filtration on a Superose12 column. For affinity chromatography, the culture media containing
CRP was diluted (1:1) in 0.1 M borate buffer saline, pH 8.3, containing 3 mM CaCl2 and passed
through the PEt-conjugated sepharose column. After collecting the flow-through and washing the
column with the same buffer, bound CRP was eluted with 0.1 M borate buffer saline, pH 8.3,
containing 5 mM EDTA. Eluted CRP was concentrated and further purified by gel filtration on a
Superose12 column. Gel filtration was carried out as described for WT CRP, except that the
column was equilibrated and eluted with TBS containing 5 mM EDTA. It was necessary that the
gel filtration of mutant CRP be performed in the presence of EDTA because, in the presence of
Ca2+, the mutant CRP bound to Superose beads (data not shown). Eluted CRP was immediately
dialyzed against TBS containing 2 mM CaCl2, stored at 4 ºC, and was used within a week. The
purity of CRP was confirmed by using denaturing SDS-PAGE.
For mouse protection experiments, both purified WT and mutant CRP were treated with
the Detoxi-Gel Endotoxin Removing Gel according to manufacturer’s instructions (Thermo).
The concentration of endotoxin in CRP preparations and buffers was determined by using the
Limulus Amebocyte Lysate kit QCL-1000 according to manufacturer’s instructions (Lonza).
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PCh-binding assay
Binding activity of CRP for PCh was evaluated by using PCh-conjugated BSA and PnC
(Statens Serum Institut) as the ligands, as described previously (7, 44). Microtiter wells (96 well
plates) were coated with 10 g/ml of PCh-BSA or PnC in TBS, overnight at 4 ºC. The unreacted
sites in the wells were blocked with TBS containing 0.5% gelatin for 45 min at room
temperature. CRP diluted in TBS containing 2 mM CaCl2, 0.1% gelatin and 0.02% Tween-20
(TBS-Ca buffer) was added in duplicate wells. After incubating the plates for 2 h at 37 ºC, the
wells were washed with TBS-Ca buffer. The assays were performed in duplicate plates. In
1plate, anti-CRP mAb HD2.4, diluted in TBS-Ca buffer, was used (1 h at 37 ºC) to detect bound
CRP. In the other plate, rabbit polyclonal anti-CRP Ab (Sigma-Aldrich), diluted in TBS-Ca
buffer, was used (1 h at 37 ºC) to detect bound CRP. HRP-conjugated goat anti-mouse IgG and
HRP-conjugated donkey anti-rabbit IgG (Thermo), diluted in TBS-Ca buffer, were used (1 h at
37 ºC) as secondary antibodies. Color was developed and the OD405 read in a microtiter plate
reader (Molecular Devices).

PEt-binding assay
Binding activity of CRP for PEt was evaluated by using 1-oleoyl-2(1, 2-biotinyl
(amidodecanoyl)-sn-glycero-3-PEt (biotinylated-PEt) (Avanti Polar Lipids, 193053) as the
ligand. Stock biotinylated-PEt (1 mg/ml in choloroform) was nitrogen-bubbled for 5 min to
evaporate chloroform and then air-dried for 1 h at room temperature to evaporate residual
chloroform. Biotinylated-PEt was resuspended in 1 ml ethanol, aliquoted, and stored at -20 ºC.
Microtiter wells (96 well plates) were coated with 10 g/ml of avidin (Sigma-Aldrich,
A9275) in TBS, for 2 h at 37 ºC. The unreacted sites in the wells were blocked with TBS
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containing 0.5% gelatin for 45 min at room temperature. After washing the wells with TBS,
biotinylated-PEt diluted in TBS (10 g/ml) was added to the wells for 2 h at 37 ºC. After
washing the wells with TBS-Ca buffer, CRP diluted in TBS-Ca buffer was added in duplicate
wells. After incubating the plates overnight at 4 ºC, the wells were washed with TBS-Ca buffer.
The assays were performed in duplicate plates. The plates were then processed exactly as
described for the PCh-binding assay.
Streptavidin could not be used to capture biotinylated PEt on the wells because, in
preliminary experiments, CRP was found to bind to streptavidin (data not shown). This was not
the case with avidin coating (data not shown).

Factor H binding assay
The binding activity of CRP for factor H was evaluated using mouse factor H (R & D
Systems) and human factor H (Complement Technology) as the ligands in solid phase ELISA.
Microtiter wells were coated with 10 g/ml of mouse factor H and human factor H in TBS,
overnight at 4 ºC. The unreacted sites in the wells were blocked with TBS containing 0.5%
gelatin for 45 min at room temperature. CRP diluted in TBS-Ca buffer was added in duplicate
wells. After incubating the plates for 2 h at 37 ºC, the wells were washed with TBS-Ca buffer.
Rabbit polyclonal anti-CRP Ab (Sigma-Aldrich), diluted in TBS-Ca buffer, was used (1 h at 37
ºC) to detect bound CRP. HRP-conjugated donkey anti-rabbit IgG (Thermo), diluted in TBS-Ca
buffer, were used (1 h at 37 ºC) as secondary antibody. Color was developed and the OD405 read
in a microtiter plate reader (Molecular Devices).
To investigate whether CRP binds to factor H in fluid phase, equal amounts of CRP and
factor H were incubated at 37oC for 30 min. Interactions between the 2 proteins was assessed by
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solid phase ELISA. Microtiter wells were coated with 10µg/ml rabbit polyclonal anti-CRP Ab
overnight at 4oC. Unreacted sites were blocked using 0.5 % gelatin at room temperature for 45
min. The CRP-factor H mixture diluted in TBS-Ca buffer was added in duplicate wells. After
incubating the plates for 2 h at 37 ºC, the wells were washed with TBS-Ca buffer. Mouse antiCRP mAb HD2.4, diluted in TBS-Ca buffer, was used (1 h at 37 ºC) to detect captured CRP
from the mixture in 1 plate. HRP-conjugated goat anti-mouse IgG diluted in TBS-Ca buffer,
were used (1 h at 37 ºC) as secondary antibody. In the other plate, factor H bound to the captured
CRP was detected using sheep polyclonal anti-mouse factor H Ab followed by HRP-conjugated
rabbit anti-sheep IgG. For both plates, color was developed and OD405 read using microtiter plate
reader (Molecular Devices).

Pneumococci
S. pneumoniae type 3, strain WU2, were made virulent by sequential i.v. passages in
mice, and were stored in aliquots at -80°C in Todd-Hewitt broth containing 0.5% yeast extract
and 10% glycerol, as described previously (7, 25). For each experiment, a separate aliquot of
frozen pneumococci was thawed. Pneumococci were then grown in Todd-Hewitt broth
containing 0.5% yeast extract and collected from mid-log phase cultures. Pneumococci were
washed and resuspended in normal saline (OD600 = 0.35 = 2.5 x 108 CFU/ml). The concentration,
purity, and viability of pneumococci were confirmed by plating on blood agar plates. This is
broth-grown pneumococci stock.
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Preparation of factor H-coated pneumococci
Broth-grown pneumococci were obtained as described above. Pneumoccocci were
centrifuged at 13,000 rpm for 5 min to obtain a pellet. The pellet was resuspended in 300 µl TBS
buffer and incubated with 10 µg of factor H at 37oC for 30 min. Excess factor H was washed by
centrifugation using TBS buffer. The bacterial pellet was resuspended in TBS buffer to obtained
desired concentration and used to coat microtiter wells for binding assays. Alternatively, brothgrown pneumococci were used to coat microtiter wells overnight at 4oC. Unoccupied sites in the
wells were blocked using 0.5 % gelatin for 45 min at room temperature.

Isolation of in vivo pneumococci from mice
Mice were infected with 5 x 107 CFU broth-grown pneumococci by intravenous route.
After 40 h blood was collected by cardiac puncture of CO2-utinized mice. Tubes containing
EDTA were used for blood collection to prevent clotting and entrapment of the bacteria. Blood
was mixed with an equal volume of saline and centrifuged at 2,200 rpm for 2 min and the
supernatant recovered. The supernatant was washed 4 times using the same conditions and
collecting the bacterial pellet each time. Finally, the pellet was spun at 13,000 rpm for 5 min and
the pellet resuspended in saline. The suspension was plated on blood agar at 37oC for 16 h and
enumerated to determine the concentration of pneumococci.

Pneumococcus-binding assay
Microtiter wells were coated with broth-grown pneumococci, factor H-coated brothgrown pneumococci or mouse-isolated pneumococci in TBS (107 CFU/100l/well) overnight at
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4 ºC. The unreacted sites in the wells were blocked with TBS containing 0.5% gelatin for 45 min
at room temperature.
For binding of CRP to pneumococci, CRP diluted in TBS-Ca buffer was added in
duplicate wells. After incubating the plates for 2 h at 37 ºC, the wells were washed with TBS-Ca
buffer. Rabbit polyclonal anti-CRP Ab diluted in TBS-Ca buffer, was used (1 h at 37 ºC) to
detect bound CRP. HRP-conjugated donkey anti-rabbit IgG diluted in TBS-Ca buffer were used
(1 h at 37 ºC) as secondary antibody. Mouse anti-CRP mAb HD2.4, diluted in TBS-Ca buffer,
was also used (1 h at 37 ºC) to detect bound CRP, followed by HRP-conjugated goat anti-mouse
IgG as secondary antibody. Color was developed and the OD405 read in a microtiter plate reader
(Molecular Devices).
For binding of factor H to pneumococci, factor H diluted in TBS-Ca buffer was added in
duplicate wells and incubated at 37 ºC for 2 h. Bound factor H was detected using sheep
polyclonal anti-mouse factor H Ab (R & D Systems) and goat polyclonal anti-human factor H
Ab dissolved in TBS buffer. HRP-conjugated rabbit anti-sheep IgG (Pierce) and HRP-conjugated
bovine anti-goat IgG (Santa Cruz Biotechnology) were then used. Color was developed and
OD405 read using microtiter plate reader (Molecular Devices).

Clearance of CRP from mouse circulation
Mice were injected i.v. with 100 lof CRP in TBS-Ca buffer through the tail vein.
Blood was collected from the tip of the tail vein after 1, 4, 8, 12, 16, 20, 24 and 28 h. The
concentration of CRP in the serum was measured by ELISA.
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Sequestration of CRP from mouse blood
To investigate the possibility that CRP could be sequestered from mouse blood by cells,
we repurified CRP from mouse blood that was spiked with purified WT CRP and quadruple
mutant CRP. CRP-spiked mouse blood was centrifuged at 8,000 rpm for 5 min and the serum
recovered. The concentration of CRP was determined by ELISA using mouse anti-CRP mAb
(HD2.4) for detection followed by HRP-conjugated goat anti-mouse IgG as secondary Ab.

Mice
Male C57BL/6J mice (Jackson ImmunoResearch Laboratories) were brought up and
maintained according to protocols approved by the University Committee on animal care.
Mice were 8-10 weeks old when used in experiments.

Mouse protection experiments
Mouse protection experiments were performed as described previously (7, 25) with
modifications. Mice were first injected i.v. with either 25 µg of WT CRP in 100 l TBS-Ca
buffer or TBS-Ca buffer only. After 30 min, mice in some groups were injected i.v. with 5 x 107
CFU of pneumococci in 100 l saline. After 16 h the mice in other groups which received only
TBS-Ca buffer were injected with 25 µg of either WT CRP or quadruple mutant CRP. This
treatment regimen was repeated 3 more times at 20 h, 24 h, and 28 h.
Survival of mice was recorded 3 times per day for 6 days. Survival curves were generated
using the GraphPad Prism 4 software. To determine p values for the differences in the survival
curves among various groups, the survival curves were compared using the software’s Logrank
test. To determine bacteremia (CFU/ml) in the surviving mice, blood was collected daily for 5
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days from the tip of the tail vein, diluted in normal saline, and plated on blood agar plates for
colony counting. Bacteremia values for dead mice was taken as >108 CFU/ml. The plotting and
statistical analyses of the bacteremia data were done using the GraphPad Prism 4 software and
Mann-Whitney two-tailed test.

Results
The E42Q/F66A/T76Y/E81A CRP quadruple mutant binds PEt more avidly than WT CRP does
Since the substitution of Thr76 to Tyr was based on the structure of SAP, and SAP also
binds to PEt (1, 8, 10) as did triple mutant CRP (46), we assessed the expression of the quadruple
mutant CRP using culture media supernatant in PEt solid phase ELISA. We observed that both
WT CRP and quadruple mutant CRP bound to PEt in a CRP concentration-dependent manner
(Fig. 3.1). These data demonstrated that the E42Q mutation had no negative effect on the binding
of CRP to PEt. On the contrary, quadruple mutant CRP was much more efficient than WT CRP
in binding to PEt since we determined that only 3% of the mutant CRP was required to achieve
an equivalent binding of WT CRP to PEt.
The binding of CRP to PEt was further evaluated using purified WT CRP and quadruple
mutant CRP. The results were consistent in showing that the quadruple mutant CRP bound more
avidly to PEt than WT CRP (Fig. 3.2).
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Figure 3.1. E42Q/F66A/T76Y/E81A CRP quadruple mutant in culture media supernatant bound to
PEt, enabling its purification by PEt affinity chromatography. Microtiter wells were coated with
avidin in TBS. The unreacted sites in the wells were blocked with gelatin. Biotinylated PEt diluted in
TBS was then added to the wells. After washing the wells with TBS, purified CRP diluted in TBS-Ca
buffer was added to the wells. Bound CRP was detected by using anti-CRP polyclonal rabbit Ab and
HRP-conjugated donkey anti-rabbit IgG. Color was developed and the OD was read at 405 nm.

Figure 3.2. The CRP quadruple mutant binds more efficiently to PEt than WT CRP. Microtiter
wells were first coated with avidin in TBS. The unreacted sites in the wells were blocked with
gelatin. Biotinylated PEt diluted in TBS was then added to the wells. After washing the wells
with TBS, purified CRP diluted in TBS-Ca buffer was added to the wells. Bound CRP was
detected by using anti-CRP mAb HD2.4 and HRP-conjugated goat anti-mouse IgG. Color was
developed and and the OD was read at 405 nm.
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The CRP quadruple mutant is expressed as a pentamer
The mutant CRP cDNA was successfully expressed in COS 7 and CHO cells and could
be purified by PEt-affinity chromatography followed by gel filtration chromatography. The
elution profiles of WT CRP and mutant CRP from the gel filtration column were almost
identical. There was a shift of only 250 l in the elution volume of the mutant CRP compared to
that of WT CRP (Fig. 3.3A). Denaturing SDS-PAGE analysis of purified WT CRP and mutant
CRP showed single bands (Fig. 3.3B) and the molecular weight of the subunits of mutant CRP
was same as that of WT CRP. The data showed that the mutant CRP was pentameric and that
substitution of Glu42, Phe66, Thr76 and Glu81 with Gln, Ala, Tyr and Ala, respectively, did not
affect the overall structure of CRP.

Figure 3.3. Overall pentameric structure of CRP quadruple mutant. A. Elution profiles of WT and
mutant CRP from the Superose12 gel filtration column are shown. WT CRP in TBS containing 2 mM
CaCl2 was applied to the equilibrated column and eluted with the same buffer. Mutant CRP in TBS
containing 5 mM EDTA was applied to the equilibrated column and eluted. Sixty fractions (0.25 ml)
were collected and protein measured (OD280) to determine the elution volume of CRP from the column.
A representative of 3 experiments is shown. B. Denaturing SDS-PAGE (4%-20% gel) of CRP (5 g). A
representative gel, stained with Coomassie brilliant blue, is shown.
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The CRP quadruple mutant does not bind to PCh or broth-grown pneumococci but binds readily
to factor H-coated pneumococci
Using 2 different PCh-containing ligands, PCh-BSA and PnC, we assessed the PChbinding activity of the mutant CRP. We found that WT CRP bound to both ligands in a CRP
concentration-dependent manner, but mutant CRP did not bind to PCh-BSA and PnC (Fig. 3.4A
and B) or to pneumococci (Fig. 3.4C).

Figure 3.4. The CRP quadruple mutant does not bind to PCh (A), PnC (B), and pneumococci (C).
Microtiter wells were coated with PCh-BSA, PnC, and pneumococci. The unreacted sites in the
wells were blocked with gelatin. Purified CRP diluted in TBS-Ca buffer was then added to the
wells. Bound CRP was detected by using anti-CRP mAb HD2.4 and HRP-conjugated goat antimouse IgG. Color was developed and and the OD was read at 405 nm. A representative of 4
experiments is shown. Similar results were obtained when polyclonal anti-CRP Ab was used to
detect ligand-bound CRP.

We also determined the binding of mutant CRP to whole pneumococci which we used in
the mouse protection experiments. These were broth-grown pneumococci, broth-grown
pneumococci coated with factor H or pneumococci isolated from mouse blood. We determined
that unlike WT CRP that bound to all types of pneumococci, mutant CRP did not bind to broth-
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grown pneumococci (Fig. 3.4C).
As hypothesized, unlike WT CRP, quadruple mutant CRP bound readily to factor Hcoated broth-grown pneumococci at physiological pH (Fig. 3.5). These results suggested that
binding of the mutant CRP to pneumococci may be occurring through the recruited factor H.
When incubated with mouse-isolated pneumococci, we found that quadruple mutant CRP bound
to the bacteria with even greater avidity (Fig. 3.6).

Figure 3.5. The CRP quadruple mutant binds to factor H-coated broth-grown bacteria. A. E42AF66A-T76Y-E81A mutant CRP binds to bacteria in TBS containing 2mM CaCl2. Microtiter wells
were coated with broth-grown pneumococci, factor H-coated broth-grown pneumococci or mouseisolated pneumococci in TBS. Unreacted sites in the wells were blocked with TBS containing
0.5% gelatin for 45 min at room temperature. CRP diluted in TBS-Ca buffer was added in
duplicate wells. Bound CRP was detected using rabbit polyclonal anti-CRP Ab diluted in TBS-Ca
buffer, followed by HRP-conjugated donkey anti-rabbit IgG diluted in TBS-Ca buffer as secondary
antibody. Color was developed and the OD read at 405 nm. B. The experiment was carried out as
in A and bound CRP was detected by using anti-CRP mAb HD2.4 and HRP-conjugated goat antimouse IgG diluted in TBS-Ca buffer. C. TBS buffer containing 5 mM EDTA was used instead of
TBS-Ca buffer in order to rule abolish binding of CRP to PCh.
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Figure 3.6. The CRP quadruple mutant binds to pneumococci isolated from mouse blood. Mice were
7
infected with 5 x 10 CFU pneumococci. After 40 h, blood was collected by cardiac puncture and used
0
to isolate the pneumococci. Microtiter wells were coated with the pneumococci at 4 C overnight. CRP
0
diluted in TBS-EDTA (5 mM) was added to duplicate wells and incubated at 37 C for 2 h. Bound CRP
was detected using Bound CRP was detected using rabbit polyclonal anti-CRP Ab diluted in TBSEDTA, followed by HRP-conjugated donkey anti-rabbit IgG diluted in TBS-Ca buffer as secondary
antibody. Color was developed and the OD read at 405 nm.

We have verified that both broth-grown pneumococci and mouse-isolated pneumococci
actually recruited factor H onto their surface. We found that factor H was detected on the surface
of broth-grown pneumococci and on mouse-isolated pneumococci (Fig. 3.7).

77

Figure 3.7. Pneumococci recruit factor H in vivo. A. Factor H binds to bacteria in vitro and in vivo.
Pneumococci were cultured in broth. Some of the pneumococci were incubated with factor H and
excess factor H removed by centrifugation. Some were used to infect mice and isolated from
mouse blood after 40 h. Microtiter wells were coated with broth-grown pneumococci, factor Hcoated pneumococci and mouse-purified pneumococci. Unoccupied sites were blocked using
gelatin. Factor recruited onto pneumococci was detected using anti-factor H Ab followed by the
appropriate HRP-tagged secondary Ab. Color was developed and read at 405 nm. B. Dose
response of factor H binding to broth-grown pneumococci. Microtiter wells were coated with
broth-grown pneumococci and unreacted sites blocked. Factor H diluted in TBS was added and
incubated. Bound factor H was detected as described for A.

The CRP quadruple mutant binds readily to immobilized factor H
We have shown that the quadruple mutant CRP binds to factor H-coated pneumococci.
We then attempted to confirm the hypothesis that the mutant CRP was binding to the
pneumococci through recruited factor H by determining the binding of the mutant CRP to
purified factor H. As expected, we confirmed that the mutant CRP in fact bound to factor H (Fig.
3.8).
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Figure 3.8. CRP quadruple mutant binds to purified factor H. Microtiter wells were coated with 10
g/ml of mouse factor H (A) and human factor H (B) in TBS, overnight at 4 ºC. The unreacted sites
in the wells were blocked with TBS containing 0.5% gelatin for 45 min at room temperature. CRP
diluted in TBS-Ca buffer was added in duplicate wells. and incubated for 2 h at 37 ºC. The wells
were washed with TBS-Ca buffer. Bound CRP was detected using rabbit polyclonal anti-CRP and
HRP-conjugated donkey anti-rabbit IgG diluted in TBS-Ca buffer. Color was developed and the OD
read in a microtiter plate reader at 405 nm.

This observation suggested that combining the E42Q and T76Y mutations resulted in a
synergistic enhancement of the factor H binding ability of E42Q in the quadruple mutant CRP. In
order to rule out the possibility that the mutant CRP could bind to circulating factor H, we
assessed its binding to factor H in fluid phase. We found that the mutant CRP did not bind to
factor H in fluid phase. This was consistent with our understanding that CRP was binding only to
immobilized factor H (Fig. 3.9).
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Figure 3.9. CRP quadruple mutant does not bind to factor H in fluid phase. Equal amounts
(28.6 g) of CRP and mouse factor H (A) and human factor H (B) were mixed and incubated
0
at 37 C for 30 min. After incubation, 10 g of the proteins were subjected to native PAGE.
The same amounts of the individual proteins were used as loading controls.

The CRP quadruple mutant can be repurified from mouse serum
We demonstrated that the mutant CRP did not bind to fluid phase factor H. However, we
eliminated any worries about the possibility of binding to serum components by repurifying it
from mouse serum spiked with quadruple mutant CRP. We also evaluated recovery from mouse
blood spiked with the protein. We showed by SDS-PAGE that the mutant CRP could be
repurified successfully from mouse serum (Fig. 3.10). Similarly, we demonstrated very good
recovery of the mutant CRP from mouse blood by ELISA. These, put together, mean that the
mutant CRP is not sequestered in mouse blood.
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Figure 3.10. The CRP quadruple mutant can be repurified from mouse serum. CRP quadruple
mutant was repurified from mouse blood that was spiked with purified WT CRP and mutant
CRP. CRP-spiked mouse blood was centrifuged at 8,000 rpm for 5 min and the serum
recovered. The concentration of CRP was determined by ELISA using mouse anti-CRP mAb
(HD2.4) for detection followed by HRP-conjugated goat anti-mouse IgG as secondary Ab.

The clearance rate of CRP quadruple mutant from mouse circulation is similar to that of WT
CRP
We evaluated the clearance of mutant CRP from mouse circulation relative to that of
WT CRP. We observed a wide variation in the time to detect the peak concentration of CRP in
mouse circulation, ranging from 1 h to 12 h after injection of CRP. The data were normalized
before plotting. The time at which the CRP concentration in serum was at its peak was taken as
zero time taking the CRP concentration at this time taken as 100%. Clearance of CRP was then
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followed at various time intervals. The results indicated that the clearance of mutant CRP in mice
was similar to that of WT CRP (Fig. 3.11). These data suggested that the mutations did not affect
the stability of CRP in vivo and that the same amount of both WT and mutant CRP could be used
in mouse protection experiments for comparing the protective effects of the 2 CRP species.

Figure 3.11. The CRP quadruple mutant is not cleared faster than WT CRP from mouse
circulation. To evaluate the clearance of WT CRP (A) and quadruple mutant CRP (B), mice were
injected with 100 g of CRP in TBS buffer containing 2 mM CaCl2. Blood was collected at
various time points, sera separated, and the concentration of CRP measured. The time at which
the CRP concentration in serum was at its peak was considered as zero time and the CRP
concentration at this time was taken as 100% injected CRP; clearance of CRP was then followed
at various time intervals.

CRP quadruple mutant which binds to factor H does not protect mice against pneumococcal
infection when administered during late stages of infection
We have demonstrated that the quadruple mutant CRP binds to factor H and could be
protective against pneumococcal infection in mice if administered later during infection. This
treatment regimen was based on the observation that WT CRP does not offer protection if not
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administered within 6 h before to 2 h after infection, and the assumption that the quadruple
mutant CRP will bind to factor H recruited by pneumococcus to facilitate complement attack. To
our dismay, such administration did not offer any protection against pneumococcus in mice.
There was no difference in mortality between mice that received either WT or mutant CRP in 4
25 g doses starting at 16 h, with mean survival time (time taken for 50% of mice to die) of 40 h
(Fig. 3.12). Mice in which WT CRP was administered at time of infection as a control had a
mean survival time of 64 h (p value = 0.04). Unlike WT CRP, mutant CRP administered at time
of infection did not have any protective effect either.
Figure 3.13 shows the bacteremia values in mice from the experiment presented in
Fig. 3.12. By the first day following infection mice that were injected with bacteria alone had
median bacteremia value of approximately 7.0 x 105 CFU/ml of blood. For the treatment groups
the median bacteremia values were 4.4 x 105 CFU/ml with WT CRP administered at 16 h, 2.2 x
105 CFU/ml and 8.1 x 104 CFU/ml respectively for mutant CRP administered at time of infection
and at 16 h. The median bacteremia value for WT CRP administered at time of infection,
however, was 2.3 x 103 CFU/ml. These data indicated that the observed deaths in Fig. 3.12 were
due to overwhelming bacterial loads as the median bacteremia values increased exponentially by
day 2 post infection when most of the mice were dying.
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Figure 3.12. Survival curves of mice infected with S. pneumoniae with CRP. Mice were injected with 5
7
x 10 CFU pneumococci, with or without 25 g single dose of either WT or quadruple mutant CRP at
time of infection or 4 doses starting at 16 h. CRP was injected first; bacteria were injected 30 min later.
Deaths were recorded 3 times a day for 6 days.

Figure 3.13. Bacteremia in mice treated with or without 25 g of either WT or CRP quadruple mutant.
Blood samples were collected from each surviving mouse for the first 5 days after infection.
Bacteremia was determined by plating. Each dot represents 1 mouse. The horizontal line in each group
8
of mice represents the median bacteremia value in that group. A bacteremia value of >10 CFU/ml
indicates a dead mouse. Groups B and D received 25 g CRP at the time of infection. Groups C and E
received 4 25 g doses of CRP starting at 16 h post infection.
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Discussion
In this study, we hypothesized that bacteria recruit factor H in vivo and use the
complement regulatory ability of the protein to prevent complement activation. We held that a
mutant CRP that does not bind to PCh but binds to factor H will allow us to investigate the
involvement of factor H in serum resistance. Using site-directed mutagenesis we generated the
quadruple mutant CRP that combined the property of not binding to PCh but with binding to
factor H. This strategy was based on previous findings that E42Q mutant CRP binds moderately
to factor at physiological pH (45) and the inability of triple mutant CRP to bind to PCh (46). We
found that: 1) Combination of the E42Q mutant CRP with the triple mutant CRP did not affect
the inability of the triple mutant CRP to bind to PCh. Thus the quadruple mutant CRP did not
bind to PCh, PnC or whole pneumococci as predicted (Fig. 3.4). 2) Combining the 2 mutations
resulted in a synergistic improvement in the binding ability of quadruple mutant CRP to factor H
(Fig. 3.8). We observed a 4 fold increase of binding of quadruple mutant CRP to factor H over
the binding of E42Q to factor H.
To assess our assertion that the resulting mutant CRP will be able to bind to factor H
recruited onto pneumococci and terminate its complement inhibiting ability, we went on to
confirm that pneumococci actually recruited factor H. We detected factor H on the surface of
broth-grown pneumococci previously exposed to factor H as well as on pneumococci isolated
from mouse but not on unexposed broth-grown pneumococci (Fig. 3.7A). We also found that
factor H bound to broth-grown pneumococci in a concentration-dependent manner (Fig. 3.7B).
When we used factor H-coated pneumococci, the results showed that the quadruple mutant CRP
bound readily to the bacteria (Fig. 3.5A), which binding we did not see with unexposed
pneumococci (Fig. 4C). Because detection of bound CRP was done using polyclonal anti-CRP
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Ab, we also detected using the pentameric-specific monoclonal Ab, HD2.4, to rule out the
possibility of false positive result due to monomerized CRP (Fig. 3.5B). WT CRP also equally
bound to factor H-exposed pneumococci since it still retains binding to PCh. To eliminate this
confounding factor, we performed the binding assay in TBS containing EDTA. The data clearly
suggested that the quadruple mutant CRP was specifically binding to factor H on the surface of
factor H-exposed pneumococci and mouse-isolated pneumococci (Fig. 3.5C and fig. 3.6). To
ascertain the quadruple mutant CRP only binds to immobilized and not circulating factor H, we
incubated CRP with human and mouse factor H in fluid phase and subjected the mixture to
native PAGE. The resulted showed no interaction between the 2 proteins in fluid phase (Fig. 3.9).
Due to concerns that the quadruple mutant CRP could be sequestered in mouse blood, we
repurified quadruple mutant CRP from quadruple mutant CRP-spiked mouse blood. We
determined that there was no sequestration since we could not detect any additional CRP band(s)
when the sample was subjected to denaturing SDS-PAGE (Fig. 3.10). The next concern was
whether the quadruple mutant CRP could be metabolized faster than WT CRP when injected. We
injected C57BL/6J mice with CRP and collected blood samples at defined time points for
analysis. Detection of CRP in recovered serum was achieved using ELISA. We determined that
the rate of clearance of the quadruple mutant CRP was not faster than that of WT CRP (Fig. 3.11)
similar to our previous observations with the Triple mutant CRP (46). Taken together, the
quadruple mutant CRP we have generated is a potential antibacterial therapeutic molecule with
unique properties that may allow it to bind to factor H-protected bacteria and render them
susceptible.
We administered the quadruple mutant CRP to mice that were infected with
pneumococcus at 25 g starting at 16 h for a total of 4 doses. Analysis of the survival data
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indicated that there was no difference in the mean survival time between the mice that received
the protein and those which did not. This was contrary to the mean survival time for mice that
received WT CRP at time of infection Fig. 3.12). When the bacteremia values were examined we
determined that the median bacteremia values for the mice that received the quadruple mutant
CRP were not as low as in mice that received WT CRP at time of infection. They were close to
those observed in mice that did not receive CRP. These data indicated that the quadruple mutant
CRP was not able to reduce bacteremia and hence mortality. It is not clear why the mutant CRP
could not improve survival when it bound to factor H on pneumococcus as demonstrated in vitro.
Although additional treatment regimens will be investigated, there is a likelihood that the
assumption that the quadruple mutant CRP would bind to recruited factor H and facilitate
complement activation and deposition may not be feasible. Furthermore, additional elements of
the immune system may be necessary for such scenario to materialize.
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CHAPTER 4
SUMMARY
Major Findings of the Project
The key findings of our work were:
1. Both triple mutant CRP and quadruple mutant CRP species possessed improved binding
to PEt as a result of the substitution of Tyr for Thr76. This enabled the use of PEtconjugated sepharose beads for purification of the mutant CRP species.
2. The mutant CRP retained HD2.4 epitope and the elution profiles of the mutant CRP
species from the gel filtration column were similar. These data confirmed that the
substitution of Phe66, Thr76, and Glu81 did not affect the overall pentameric structure of
the proteins.
3. Neither triple mutant CRP nor quadruple mutant CRP bound to PCh, PnC, and
pneumococci. The EA4.1 epitope was lost in the mutant CRP, indicating that the PChbinding site was successfully prohibited.
4. Mutant CRP species were not sequestered in mouse blood/serum and could be
successfully repurified from CRP-spiked mouse blood/serum.
5. The rate of clearance of mutant CRP was similar to or even slower than that of wild-type
CRP, suggesting that there was enough mutant CRPs available in mice during in vivo
experiments.
6. The triple mutant CRP did not protect mice against pneumococcal infection because the
PCh-binding site of CRP was necessary, at least, for the initial stages of infection.
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7. The quadruple mutant CRP bound to pneumococci only after the pneumococci were pre
incubated with factor H or when pneumococci were isolated from mice. This suggested
that the binding of the mutant CRP to pneumococci was mediated by factor H.
8. We showed that the quadruple mutant CRP effectively bound to purified factor H in a
dose-dependent manner.
9. Mutant CRP bound to factor H only when immobilized; CRP did not bind to factor H in
the fluid phase.
10. We have demonstrated that combination of the E42Q and the triple mutations results in a
highly synergistic factor H-binding ability in the quadruple mutant CRP.
11. We confirmed that pneumococci recruit factor H onto their surface both in vitro and in
vivo. This observation was consistent with the hypothesis that pneumococci may recruit
factor H to achieve serum resistance.

Pitfalls
The main difficulty we faced was with the expression of the quadruple mutant CRP
cDNA. Although we successfully expressed the cDNA, the expression was so low that we
invested a lot of time and material wealth in the accumulation of enough protein for the
experiments. The problem seemed to be associated with undefined additional properties of the
mutant CRP. We observed that the older the expressing CHO cells became and as they die, we
started to lose expressed protein The loss ranged from an initial expression level of about 2 mg/l
down to about 0.4 mg/ml compared to up to 10 mg/ml expression level with the triple mutant
CRP under serum-free medium adapted conditions. This observation suggested that dead CHO
cells may be exposing some ligands to which the mutant CRP bound. It was not clear if CRP
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bound to such ligands lost their native structure because attempts to detect CRP on cell pellets
immobilized onto ELISA plates were not successful.
We assumed that WT CRP failed to protect mice against pneumococcal infection in the
late stages of infection because pneumococci-recruited factor H prevents the activation and
deposition of complement on the bacterial surface. It is not clear whether binding of mutated
CRP to pneumococci-coated factor H will indeed translate into the elimination of those
complement-inhibiting properties of factor H. Is there a scenario where mutated CRP
preoccupies factor and allow WT CRP to activate and deposit complement on the bacteria?
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